Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice
dc.contributor.author | Evans, M | |
dc.contributor.author | Morgan, AR | |
dc.contributor.author | Bain, SC | |
dc.contributor.author | Davies, S | |
dc.contributor.author | Hicks, D | |
dc.contributor.author | Brown, P | |
dc.contributor.author | Yousef, Z | |
dc.contributor.author | Dashora, U | |
dc.contributor.author | Viljoen, A | |
dc.contributor.author | Beba, H | |
dc.contributor.author | Strain, WD | |
dc.date.accessioned | 2022-07-21T08:59:32Z | |
dc.date.issued | 2022-01-19 | |
dc.date.updated | 2022-07-20T17:23:28Z | |
dc.description.abstract | While glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, are among the most effective drugs for treating people with type 2 diabetes (T2D), they are clinically under-utilised. Until recently, the only route for semaglutide administration was via subcutaneous injection. However, an oral formulation of semaglutide was recently licensed, with the potential to address therapy inertia and increase patient adherence to treatment, which is essential in controlling blood glucose and reducing complications. The availability of oral semaglutide provides a new option for both clinicians and patients who are reluctant to use an injectable agent. This has been of particular importance in addressing the challenge of virtual diabetes care during the COVID-19 pandemic, circumventing the logistical problems that are often associated with subcutaneous medication administration. However, there remains limited awareness of the clinical and economic value of oral semaglutide in routine clinical practice. In this article, we present our consensus opinion on the role of oral semaglutide in routine clinical practice and discuss its value in reducing the burden of delivering diabetes care in the post-COVID-19 pandemic period of chronic disease management. | en_GB |
dc.description.sponsorship | Novo Nordisk | en_GB |
dc.format.extent | 225-240 | |
dc.format.medium | Print-Electronic | |
dc.identifier.citation | Vol. 13, pp. 225-240 | en_GB |
dc.identifier.doi | https://doi.org/10.1007/s13300-021-01201-z | |
dc.identifier.uri | http://hdl.handle.net/10871/130314 | |
dc.identifier | ORCID: 0000-0002-6826-418X (Strain, W David) | |
dc.identifier | ScopusID: 56602727900 | 9244119500 (Strain, W David) | |
dc.identifier | ResearcherID: Y-9858-2019 (Strain, W David) | |
dc.language.iso | en | en_GB |
dc.publisher | Springer | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/35044569 | en_GB |
dc.rights | © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. | en_GB |
dc.subject | Oral semaglutide | en_GB |
dc.subject | Type 2 diabetes | en_GB |
dc.subject | Glucagon-like peptide-1 receptor agonists | en_GB |
dc.title | Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-07-21T08:59:32Z | |
dc.identifier.issn | 1869-6953 | |
exeter.place-of-publication | United States | |
dc.description | This is the final version. Available from Springer via the DOI in this record. | en_GB |
dc.description | Data sharing is not applicable to this article as no datasets were generated or analysed during the current study. | en_GB |
dc.identifier.eissn | 1869-6961 | |
dc.identifier.journal | Diabetes Therapy | en_GB |
dc.relation.ispartof | Diabetes Ther, 13(2) | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
dcterms.dateAccepted | 2021-12-24 | |
dc.rights.license | CC BY-NC | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2021-12-24 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-07-21T08:50:48Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-07-21T08:59:41Z | |
refterms.panel | A | en_GB |
refterms.depositException | publishedGoldOA | |
refterms.dateFirstOnline | 2022-01-19 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © The Author(s) 2022. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.